Aldosterone and cardiovascular disease: the heart of the matter
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aldosterone contributes to the endocrine basis of heart failure and studies on cardiac aldosterone signaling have reinforced its value as a therapeutic target. Recent focus has shifted to new roles of aldosterone that appear to depend on co-existing pathologic stimuli, cell type, and disease etiology. This review evaluates recent advances in mechanisms underlying aldosterone-induced cardiac disease and highlights the interplay between aldosterone and Ca2+ and calmodulin dependent protein kinase II, whose hyperactivity during heart failure contributes to disease progression. Increasing evidence implicates aldosterone in diastolic dysfunction, and there is need to develop more targeted therapeutics such as aldosterone synthase inhibitors and molecularly specific anti-oxidants. Despite accumulating knowledge, many questions still persist and will likely dictate areas of future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“Clear evidence for the therapeutic value of aldosterone blockade in patients with severe heart failure was provided by the RALES and EPHESUS trials [2], [3] as well as in heart failure patients with mild symptoms [4].”
MethodFunder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554
Jauslin, M. L., Meier, T., Smith, R. A. J., & Murphy, P. M. (2003) · The FASEB Journal · doi:10.1096/fj.03-0240fje · Cited by 358
Calhoun, D. A., White, W. B., Krum, H., Guo, W., Bermann, G., Trapani, A., Lefkowitz, M. P., & Ménard, J. (2011) · Circulation · doi:10.1161/circulationaha.111.029892 · Cited by 227
Cited by
Aldosterone synthase inhibitors in cardiovascular and renal diseases
Namsolleck, P., & Unger, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft402 · Cited by 63
“Other ROS-dependent kinases, such as CaMKII or PKA, are also involved in aldosterone-mediated signalling [5].”
Gorenek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G. Y. H., Mahajan, R., Potpara, T., et al. (2018) · EP Europace · doi:10.1093/europace/euy051 · Cited by 43
Role of Aldosterone Blockade in Resistant Hypertension
Egan, B. M., & Li, J. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.004 · Cited by 33
Management of hypertension and heart failure in patients with Addison's disease
Inder, W. J., Meyer, C., & Hunt, P. J. (2015) · Clinical Endocrinology · doi:10.1111/cen.12592 · Cited by 20
Metadata
- Authors
- He, B. J., & Anderson, M. E.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 24
- Issue
- 1
- Pages
- 21-30
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W2002662427
- Cited by
- 65
- References
- 7
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aldosterone and cardiovascular disease: the heart of the matter. https://app.cochat.ai/papers/10.1016/j.tem.2012.09.004
- The paper
- He, B. J., & Anderson, M. E. (2013). Aldosterone and cardiovascular disease: the heart of the matter. Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2012.09.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.